The five ways pharma developers can get the most out of early engagement with payers and regulators when plotting their clinical and commercial evidence plans.
Bengt Anell, Sangeeta Budhia, Richard Macaulay
Advertisement
Bengt Anell, Senior Director, PAREXEL International, Sangeeta Budhia, Senior Director, PAREXEL International, and Richard Macaulay, Principal Consultant, PAREXEL International
Articles by Bengt Anell, Sangeeta Budhia, Richard Macaulay
As regulators lower evidentiary requirements for approval to speed development and review of new drugs for unmet medical needs, payers are demanding more data to justify price premiums. Companies need to be strategic in how they navigate these complexities, write Bengt Anell, Sangeeta Budhia and Richard Macaulay.
Advertisement
Latest Updated Articles
5 Ways to Ensure Early Engagement with Payers and Regulators Pays OffPublished: September 4th 2017 | Updated:
Aligning Early Advice with Long-Term PlanningPublished: November 1st 2017 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
Roundup: Biopharmaceutical Industry Activity Accelerates with Focus on Rare Diseases and Novel Therapies
3
How are Updates to FDA's Processes Impacting Medical Affairs Teams?
4
Advancing Neuroscience and Rare Disease Innovation
5
